The Ozempocalypse Is Nigh
The post says the FDA has ended the GLP-1 shortage, so compounding pharmacies must stop selling cheap semaglutide and tirzepatide. It reviews the legal workarounds, the pharma companies' response, and the higher prices patients now face.
